Intravenous dihydroergotamine for inpatient management of refractory primary headaches

2011132 citationsJournal Article

Authors

Peter J. Goadsby · NIHR Maudsley Biomedical Research Centre

Abstract

Intravenous dihydroergotamine is well-tolerated, and longer treatments produce a better outcome. Nausea is the most common adverse effect, and its control is associated with a better outcome.

Topics & Keywords

Migraine and Headache Studies Trigeminal Neuralgia and Treatments Sympathectomy and Hyperhidrosis Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 77, Issue 20, pp. 1827-1832

DOI: 10.1212/wnl.0b013e3182377dbb

Field-Weighted Citation Impact: 3.64